Theranica set out to develop a product that was as effective as leading prescription medications, with a high safety profile, at an affordable price. Nerivio was developed to provide people with an affordable long-term solution. Offered at $99, the Nerivio only needs to be replaced after 12 uses.
Nerivio is uniquely placed on the upper arm and is the first smartphone-controlled migraine wearable to receive De Novo clearance from the U.S. Food and Drug Administration.
Nerivio uses Remote Electrical Neuromodulation, utilizing an endogenous neurological mechanism called Conditioned Pain Modulation, which has been extensively studied and proven to be as effective as pharmacological options. Moreover, the data show that the efficacy of Nerivio is sustained over a 24 to 48-hour period, which is quite rare with a non-pharmacological therapy.
What is perhaps even more important, is that Nerivio shows consistency across multiple treatments, offering a safe, long-term therapeutic alternative with minimal side effects and no contraindications.